scholarly journals Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors

ACS Omega ◽  
2019 ◽  
Vol 4 (22) ◽  
pp. 19895-19904 ◽  
Author(s):  
Zsófia Kutil ◽  
Jana Mikešová ◽  
Matthes Zessin ◽  
Marat Meleshin ◽  
Zora Nováková ◽  
...  
Keyword(s):  
Hdac Inhibitors ◽  
Activity Assay ◽  
Continuous Activity

Enhanced HDAC (Histone Deacetylase) Enzyme Activities in Blood CD 34 + Cells in Patients with Agnogenic Myeloid Metaplasia.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4218-4218 ◽  
Author(s):  
Jen-Chin Wang ◽  
Kirugaval Hemavathy ◽  
Kathir Suppiah ◽  
Tsong S. Chang ◽  
Allan D. Novetsky
Keyword(s):  
Transcriptional Repression ◽  
Hdac Inhibitors ◽  
Type Ii ◽  
Activity Assay ◽  
Myeloid Metaplasia ◽  
Hdac Activity ◽  
Cd 34 ◽  
Agnogenic Myeloid Metaplasia ◽  
Myeloproliferative Diseases ◽  
Preliminary Study

Abstract We previously reported that Blood TIMP-1, TPO levels are elevated and blood MMP-3, bone marrow SDF-1 levels are decreased in patients with Agnogenic Myeloid Metaplasia (AMM). We postulated that these finding are likely related to the defects in TGF-β 1 pathway especially the TGF-β Type II (TGF β RII) receptor defects, resulting in enhanced TGF-β 1 activity. Decreased TGF β RII mRNA has been reported in blood CD 34 + cells previously. HDAC have been found lately to play an important role in the transcriptional repression and silencing of genes in cancer and HDAC inhibitors have proven to be useful tools in the treatment of cancer by reversre the silenced genes. We therefore measured HDAC activity in Blood CD 34 + cells to further explore the mechanism of the TGF β R II defects in this disease. HDAC activity was measured using the HDAC Colorimetric Activity Assay/Drug discovery Kit (BIOMOL Research Lab. Inc. PA). Nine patients with AMM and other patients with myeloproliferative diseases and normal volunteers used as controls were studied. The HDAC activities were expressed as the amount of the released Deacetylated Products (uM) as shown in Table 1. This preliminary study suggests that HDAC activity is enhanced in some patients with AMM, and could be responsible for the decreased TGF β RII expression. HDAC inhibitors could therefore serve as valuable tools in the treatment of this disease. Table 1 AMM MPD Controls Mean ± SE 19 ± 9.2 1.05 ± 0.54 2.10± 0.71

scholarly journals Development of an ELISA-Based HDAC Activity Assay for Characterization of Isoform-Selective Inhibitors

2015 ◽  
Vol 20 (10) ◽  
pp. 1277-1285 ◽  
Author(s):  
Geetha Padige ◽  
Ahmed T. Negmeldin ◽  
Mary Kay H. Pflum
Keyword(s):  
Mammalian Cell ◽  
Recombinant Proteins ◽  
Hdac Inhibitors ◽  
Enzyme Linked Immunosorbent Assay ◽  
Activity Assay ◽  
Hdac Activity ◽  
Anticancer Properties ◽  
The Individual ◽  
Hdac Proteins

Histone deacetylase (HDAC) proteins are promising targets for cancer treatment, with several HDAC inhibitors used clinically as anticancer drugs. Most HDAC inhibitors nonspecifically interact with all or many of the 11 HDAC isoforms. Isoform-selective HDAC inhibitors would be useful tools to dissect the individual functions of HDAC proteins in cancer formation, in addition to potentially displaying effective anticancer properties. We report here a robust HDAC activity assay for screening selective HDAC inhibitors, which is inspired by the traditional enzyme-linked immunosorbent assay (ELISA). The key feature of the ELISA-based HDAC activity assay is use of mammalian cell–derived HDAC isoforms instead of recombinant proteins. Importantly, the assay was validated with several known HDAC inhibitors. The ELISA-based HDAC activity assay will facilitate the characterization of isoform-selective HDAC inhibitors against mammalian cell–derived HDAC proteins, which will enhance HDAC-centered cancer research and provide a foundation for anticancer drug development.

Kinetic model discrimination of penicillin G acylase thermal deactivation by non-isothermal continuous activity assay

2018 ◽  
Vol 187 ◽  
pp. 79-86 ◽  
Author(s):  
Matthew A. McDonald ◽  
Lukas Bromig ◽  
Martha A. Grover ◽  
Ronald W. Rousseau ◽  
Andreas S. Bommarius
Keyword(s):  
Kinetic Model ◽  
Penicillin G Acylase ◽  
Penicillin G ◽  
Model Discrimination ◽  
Thermal Deactivation ◽  
Activity Assay ◽  
Continuous Activity

Azocoll protease activity assay

2007 ◽  
Author(s):  
Naxin Jiang ◽  
Nguan Soon Tan ◽  
Bow Ho ◽  
Jeak Ling Ding
Keyword(s):  
Protease Activity ◽  
Activity Assay

Development of novel HDAC inhibitors to selectively co-inhibit HDAC8 and HDAC10 in childhood cancer

2016 ◽  
Vol 228 (03) ◽  
Author(s):  
F Kolbinger ◽  
E Koeneke ◽  
J Senger ◽  
T Heimburg ◽  
T Bayer ◽  
...  
Keyword(s):  
Childhood Cancer ◽  
Hdac Inhibitors

Differentiation of myeloid leukemia cells by HDAC-inhibitors

2004 ◽  
Vol 216 (03) ◽  
Author(s):  
S Schulze ◽  
B Busche ◽  
H Nau ◽  
D Eikel ◽  
L Schweigerer ◽  
...  
Keyword(s):  
Myeloid Leukemia ◽  
Hdac Inhibitors ◽  
Leukemia Cells

HDAC inhibitors impair Fshb subunit expression in murine gonadotrope cells

2019 ◽  
Author(s):  
Gauthier Schang ◽  
Chirine Toufaily ◽  
Daniel J Bernard
Keyword(s):  
Hdac Inhibitors ◽  
Subunit Expression
Sign in / Sign up

Export Citation Format

Share Document